NurExone Biologic Inc. is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on Sept. 9-10, 2026, in New York City. Yoram Drucker, the company’s Co-Founder, Chairman and Vice President of Strategic Development, will give an investor presentation from 9:10 to 9:30 a.m. EDT on Sept. 9 in Room 1 at The Westin New York Grand Central and participate in scheduled one-on-one meetings with investors. NurExone is developing exosome-based regenerative therapies for central nervous system injuries. Its lead product, ExoPTEN, has generated preclinical data supporting potential treatment of acute spinal cord and optic nerve damage, while the company is preparing for potential clinical development and working on manufacturing and commercial capabilities in the United States. NurExone is listed on the TSX Venture Exchange, OTCQB and Frankfurt Stock Exchange.